Compare iShares China Large-Cap ETF (FXI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares China Large-Cap ETF trades at $34.25 (market cap $3.86B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 2.6× iShares China Large-Cap ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| FXI | XBI | |
|---|---|---|
Market Cap | $3.86B | $10.11B |
Volume | 16,323,837 | 12,903,266 |
52-Week High | $41.08 | $169.55 |
52-Week Low | $31.59 | $104.99 |
Typical Hold Time | 150 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $33.45 with minimal daily movement (+0.09%), reflecting cautious sentiment amid mixed technical signals. The ETF shows bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. Recent news highlights China's economic challenges including industrial overcapacity and trade tensions, while corporate profits showed strong growth in Q2 2026. The ETF trades at a significant discount to U.S. equities with a P/E ratio approximately half that of the S&P 500.
FXI offers value exposure to Chinese large-caps but faces headwinds from geopolitical risks and economic rebalancing. The Trump-Xi summit provided limited progress on trade tensions, while China's export controls and domestic stimulus measures create uncertainty. Institutional sentiment remains divided between the valuation opportunity and persistent political risks.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
